BALLARD PARTNERS

Lobbying for GENMAB US, INC. · Biotechnology company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · New Jersey · House · Senate · $60,000.00 income · posted Oct 15, 2025

Lobbying activity 1

Health Issues

Guidance on legislation and regulations regarding the creation and development of differentiated antibody therapeutics.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.